JupiteX Get the app
Health & Medicine18 Nov 2026 · about 7 min

173 countries adopt AMR plans, but testing and treatment gaps persist – WHO

The brief

The supplied headlines report that 173 countries have adopted antimicrobial resistance plans. AMR occurs when microbes, including bacteria, become less responsive to medicines used against them. It matters because infections can become harder to treat when effective medicines are not identified or available. The headline points to a gap between adopting plans and putting effective testing and treatment within reach. Laboratory testing can help identify the germ causing an infection and which medicines may work against it. If testing is unavailable or delayed, clinicians may have less information when choosing treatment. The headline does not specify which countries or facilities have these gaps, or how many people are affected. It also does not describe the plans’ particular measures. The figures and headlines show both broad policy action and remaining challenges. A plan can set direction, but testing and treatment access still matter in practice. Other supplied headlines point to a growing threat in Europe and to animal health investment as part of AMR control. The provided text gives no details about timelines, funding, or whether the reported gaps are improving.

01

What have 173 countries done about antimicrobial resistance, and what testing and treatment gaps remain?

The supplied headlines report that 173 countries have adopted antimicrobial resistance plans. AMR occurs when microbes, including bacteria, become less responsive to medicines used against them. It matters because infections can become harder to treat when effective medicines are not identified or available. The headline points to a gap between adopting plans and putting effective testing and treatment within reach.

Laboratory testing can help identify the germ causing an infection and which medicines may work against it. If testing is unavailable or delayed, clinicians may have less information when choosing treatment. The headline does not specify which countries or facilities have these gaps, or how many people are affected. It also does not describe the plans’ particular measures.

The figures and headlines show both broad policy action and remaining challenges. A plan can set direction, but testing and treatment access still matter in practice. Other supplied headlines point to a growing threat in Europe and to animal health investment as part of AMR control. The provided text gives no details about timelines, funding, or whether the reported gaps are improving.

02

What is antimicrobial resistance, and how does it make infections harder to treat?

Antimicrobial resistance, or AMR, is a change in microbes that makes medicines used against them less effective. Antimicrobials include antibiotics, which act against bacteria. Resistance is a property of the microbes, not a person’s body becoming resistant. The supplied headlines identify AMR as a major concern but do not define its biology; this explanation uses established scientific knowledge.

For example, a bacterial infection may not respond to an antibiotic that would usually help. A laboratory can test a sample to see which medicines inhibit the bacteria and which do not. When a medicine no longer works well, clinicians may need to choose another suitable treatment. The headlines report that testing and treatment gaps persist, but do not give details about particular tests or medicines.

AMR can make infections more difficult to treat and can limit treatment choices. One supplied headline reports a WHO projection that AMR could cause 39 million deaths over 25 years. Another says Europe faces a growing threat from drug-resistant superbugs. The headlines do not provide further estimates or explain how those risks vary between places.

03

How many deaths could AMR cause over the next 25 years, according to the WHO?

The supplied headline reports a WHO projection that antimicrobial resistance could kill 39 million people over 25 years. The figure describes a possible future toll, rather than deaths already recorded. AMR is resistance by microbes to medicines used against them. The source text does not give the assumptions behind the projection or explain how the estimate was calculated.

Resistance can make some infections harder to treat because medicines that once worked may be less effective. The headline list also reports that 173 countries have adopted AMR plans, while testing and treatment gaps persist. These facts show that countries are responding, but the supplied text does not connect the 39 million projection to particular regions, infections, or gaps.

The 25-year period is the only timeframe given for the projection. The same collection of headlines describes Europe as facing a growing threat from drug-resistant superbugs and says investment in animal health is critical to curbing AMR. It does not state whether the projected deaths can be prevented, give a target for reducing them, or describe specific next steps.

04

What can happen to patients when a resistant infection is not detected or the right treatment is unavailable?

The supplied headlines identify persistent testing and treatment gaps, but they do not describe what happens to individual patients. In general medical knowledge, a resistant infection may not respond to a medicine that would normally treat it. If resistance is not recognized, a patient may initially receive an ineffective treatment, allowing the infection to continue or worsen. These are possible consequences, not outcomes stated in the supplied text.

A laboratory test can help identify the microbe and check its response to medicines. If the test shows resistance, a clinician can consider another treatment that is likely to work, when one is available and appropriate. If testing is missing or the right medicine is unavailable, that choice becomes harder. The source headlines do not give patient examples or describe how often these problems occur.

The headline about 173 countries adopting AMR plans alongside continuing testing and treatment gaps highlights why implementation matters. Another headline cites a WHO projection of 39 million deaths over 25 years, but it does not attribute individual deaths to missed tests or unavailable treatment. The source provides no further patient-level figures or outcomes.

05

How can laboratory tests show whether an infection is resistant to particular medicines?

The supplied headlines say testing gaps persist, but they do not explain how laboratories test for resistance. In general, a laboratory can examine a sample from an infection, grow the bacteria, and expose them to selected medicines. The results can show whether a medicine stops bacterial growth or whether the bacteria continue growing despite it. This gives clinicians useful information when choosing treatment.

One common approach is to measure bacterial growth around a medicine, or to determine the lowest medicine concentration that prevents visible growth. These methods help classify bacteria as susceptible or resistant under established standards. Tests must be interpreted alongside a patient’s condition; a laboratory result alone does not select treatment. These details are general scientific knowledge, not procedures described in the supplied headlines.

The source text reports that 173 countries have adopted AMR plans while testing and treatment gaps remain. It gives no figures for laboratory capacity, turnaround time, test types, or access by country. Its headline about a WHO projection of 39 million deaths over 25 years underscores the scale of concern, but does not state how improved testing would change that estimate.

06

Why does controlling AMR involve animal health as well as human health?

Antimicrobial resistance affects microbes, and controlling it involves how medicines are used in both people and animals. The supplied headlines explicitly connect the two: one says investment in animal health is critical to curbing AMR. The source does not explain the specific policies or pathways behind that claim. The broader explanation here draws on established knowledge about the shared risks of resistance.

Resistant microbes can move among animals, people, and the environment. The use of antimicrobial medicines in animals can also create conditions in which resistant microbes become more common. For example, resistant bacteria associated with animals may reach people through contact or food. These are general examples; the supplied text does not give a specific animal, disease, or transmission case.

A separate headline reports that 173 countries have adopted AMR plans, while gaps in testing and treatment persist. Taken together, the headlines frame animal health investment as part of a wider response, not a standalone solution. The supplied text gives no budget, country list, or animal-health program details, but it identifies investment as important to curbing AMR.

07

How do antibiotics affect bacteria, and how can resistant bacteria become more common over time?

Antibiotics are medicines that kill bacteria or stop them from growing. Antimicrobial resistance develops when bacteria are able to survive or grow despite a medicine that would usually affect them. The supplied headlines mention AMR and antibiotics but do not explain this process; the explanation here reflects established scientific knowledge. Antibiotics do not treat viral infections.

Some bacteria may already carry traits that help them survive a particular antibiotic, or may acquire resistance through genetic changes or by receiving resistance genes from other bacteria. When antibiotics are used, susceptible bacteria are more likely to be removed, while resistant ones may survive and reproduce. This natural selection can make resistant bacteria more common in a population over time.

The source headlines report that 173 countries have adopted AMR plans, yet testing and treatment gaps persist. They also cite a WHO projection of 39 million deaths over 25 years and describe a growing threat from drug-resistant superbugs in Europe. The text does not detail antibiotic-use patterns or specific prevention measures, but includes a headline about public help to protect essential medicines.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web